ACADIA Pharmaceuticals Inc. (0A4W.IL) Stock Price, News, Quote & History
The article provides the stock price, news, quote, and historical data for ACADIA Pharmaceuticals Inc. (0A4W.IL) from Yahoo Finance. As of July 23 at 9:00:00 p.m. GMT+1, the stock was trading at 18.38 USD, up 2.11%. The page offers various financial information sections like summary, chart, historical data, and performance.
ACADIA Pharmaceuticals Inc. (ACAD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) after the company announced that its drug remlifanserin "narrowly missed" its primary endpoint in a Phase 2 clinical trial for Alzheimer's disease psychosis. This news led to a significant drop in Acadia's stock price. The law firm is encouraging affected investors to contact them to learn more about the investigation and a potential class action lawsuit.
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts
This article provides stock forecasts for ACADIA Pharmaceuticals Inc. (ACAD) through Yahoo Finance. The content is very minimal, indicating an error in retrieving the actual data, and primarily consists of navigation links and market summaries from Yahoo Finance for various global regions and asset classes.
Needham cuts target for ACADIA Pharmaceuticals stock from USD 40.00 to USD 35.00
Needham has lowered its price target for ACADIA Pharmaceuticals (ACAD) from $40.00 to $35.00, while maintaining a Buy rating, following mixed results from the RADIANT study. This revision comes despite the company reporting a 16.40% increase in Q2 2026 revenue to $308.00 million, surpassing earnings expectations. Goldman Sachs reiterated a Sell rating with a $17.00 target after the trial results, indicating increased clinical uncertainty for the company's pipeline despite strong commercial performance.
Acadia Pharmaceuticals Stock Extends A 7-Day Losing Streak To A 25% Loss
Acadia Pharmaceuticals (ACAD) stock has experienced a significant downturn, losing 24.7% over seven consecutive trading days, erasing approximately $1.1 billion from its market value. This decline, which is primarily company-specific rather than market-driven, has left the stock at its lowest close in the past year. Despite the stock's poor performance, the company's fundamentals, including revenue growth and valuation multiples, suggest a more robust business than the stock price reflects.
Acadia Pharmaceuticals stock hits 52-week low at $19.66
Acadia Pharmaceuticals (ACAD) stock has dropped to a 52-week low of $19.66, reflecting a significant year-to-date decline and a challenging year for the company. Despite the price drop, InvestingPro data suggests the stock is oversold and undervalued, with a low P/E ratio of 9.16 and a PEG ratio of 0.14. The decline follows mixed results from its Phase 2 RADIANT program for remlifanserin, leading several analysts to adjust their price targets.
Acadia Pharmaceuticals stock hits 52-week low at $19.66 By Investing.com
Acadia Pharmaceuticals (ACAD) stock has reached a 52-week low of $19.66, marking a significant decline of 36% from its high and a 24.56% year-to-date drop. Despite this, InvestingPro data suggests the stock is undervalued, trading at a P/E ratio of 9.16 and a PEG ratio of 0.14. The recent drop follows mixed results from its Phase 2 RADIANT program, which led several analysts to adjust their price targets.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Pomerantz LLP is investigating potential claims against ACADIA Pharmaceuticals Inc. following a significant drop in stock price. This investigation comes after Acadia's remlifanserin drug narrowly missed its primary endpoint in a Phase 2 clinical trial for Alzheimer's disease psychosis, leading to analyst downgrades and a substantial decrease in share value. The law firm is advising affected investors to contact them regarding possible securities fraud or unlawful business practices.
Acadia Pharmaceuticals stock hits 52-week low at $19.66 By Investing.com
Acadia Pharmaceuticals (ACAD) stock has fallen to a 52-week low of $19.66, representing a 36% decrease from its high and a 24.56% year-to-date decline. Despite this, InvestingPro data suggests the stock is undervalued and in oversold territory, with a low P/E ratio of 9.16 and a PEG ratio of 0.14. The decline follows mixed results from the Phase 2 portion of the RADIANT program, which led several analysts to adjust their price targets.
What Comes Next For Acadia Pharmaceuticals After A 23% Drop
Acadia Pharmaceuticals (ACAD) has seen a 23.1% drop in share price since the start of 2026, despite initial analyst expectations for double-digit revenue growth and strong profit margins. The article explores the two prevailing narratives for the company: an optimistic view based on product approvals and pipeline, and a cautious view highlighting product concentration and patent risks. It emphasizes tracking reported net margins and label wins to assess the company's future potential.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Pomerantz LLP is investigating potential securities fraud claims against ACADIA Pharmaceuticals Inc. following a significant drop in its stock price. This investigation was prompted by Acadia's announcement that its drug, remlifanserin, "narrowly missed" the primary endpoint in a Phase 2 clinical trial for Alzheimer's disease psychosis, causing a 12.78% stock decline. Investors are encouraged to contact Pomerantz LLP for information regarding joining a potential class action lawsuit.
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
Acadia Pharmaceuticals has secured a patent allowance from the USPTO for weight-banded dosing of its Rett syndrome drug, Daybue, extending U.S. patent protection from July 2036 to March 2041. This extension provides nearly five additional years of exclusivity for trofinetide, bolstering its commercial potential and delaying generic competition. Daybue has shown significant sales growth and recently received marketing authorization in Europe, expanding its global reach.
Acadia debuts 63,000 sq. ft. Princeton office, biopharma hub designed by Ware Malcomb
Acadia Pharmaceuticals Inc. has opened its new 62,600-square-foot U.S. East Coast headquarters in Princeton, designed by Ware Malcomb. The facility at 210 Carnegie Center in West Windsor features a two-floor layout, with the first floor dedicated to daily operations and the upper level serving as a conference and training center. The design incorporates biophilic principles and allows for color-changing lighting to reflect company announcements and holidays.
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
Acadia Pharmaceuticals announced that the USPTO has issued a Notice of Allowance for a U.S. patent covering weight-banded dosing of trofinetide for Rett syndrome. This patent is expected to extend intellectual property protections for trofinetide (marketed as DAYBUE and DAYBUE STIX) in the United States until March 2041, nearly five years beyond the previous July 2036 expiry. The company emphasizes this strengthens its commitment to the Rett syndrome community and the product's long-term availability.
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
Acadia Pharmaceuticals announced that the USPTO has issued a Notice of Allowance for a U.S. patent application covering weight-banded dosing of trofinetide for Rett syndrome. This allowance is expected to extend patent protections for trofinetide in the U.S. through March 28, 2041, nearly five years beyond the previous July 2036 expiration. Trofinetide is marketed as DAYBUE for the treatment of Rett syndrome in adults and pediatric patients.
Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent
Acadia Pharmaceuticals announced that the US Patent and Trademark Office has issued a notice of allowance for a patent related to the dosing of Trofinetide. This development was reported late Monday. To read the full details of this patent allowance, a premium subscription to MT Newswires is required.
Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push
Acadia Pharmaceuticals (ACAD) stock has pulled back significantly after mixed Phase II data for remlifanserin and the decision to proceed to Phase III. Despite a low P/E ratio, the market seems to be heavily discounting the company, raising questions about whether the current price reflects its long-term potential and pipeline commitment. Investors are left to consider if the existing trials and product set justify its valuation relative to industry benchmarks.
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
Acadia Pharmaceuticals announced positive Phase 2 results for remlifanserin in Alzheimer's Disease Psychosis (ADP), showing a significant reduction in hallucinations and delusions with the 60 mg dose, and a favorable safety profile. The company plans to continue its Phase 3 program, removing the 30 mg dose arm, and will present detailed findings at the CTAD conference. Remlifanserin is a novel 5HT2A receptor inverse agonist with no FDA-approved treatment currently available for ADP, addressing a high unmet medical need.
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ)
Acadia Pharmaceuticals (ACAD) saw its stock drop almost 7% on Friday, following a 13% decline the previous day. This downturn resulted from the company reporting topline Phase 2 results for its RADIANT study, where the drug remlifanserin narrowly missed its primary endpoint for Alzheimer's disease psychosis. Despite the setback, analysts note continued support from existing commercial products and ongoing Phase 3 development for remlifanserin.
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
Acadia Pharmaceuticals' (ACAD) stock dropped 13% after its Phase II RADIANT study for remlifanserin in Alzheimer's disease psychosis narrowly missed its primary efficacy endpoint. Despite this, the company plans to continue with Phase III development of the 60 mg dose, noting favorable safety results and stronger performance on key secondary endpoints. There is a significant unmet medical need for ADP treatments, as no FDA-approved drugs specifically target the condition.
ACADIA Pharmaceuticals (ACAD) Drops 8.6% to $23.25
ACADIA Pharmaceuticals (ACAD) shares dropped 8.6% to $23.25 after the company announced its remlifanserin clinical study failed to meet its primary endpoint. This setback is a significant blow to the biotech's pipeline expansion efforts and has led investors to reassess ACADIA's development portfolio. The company's future growth trajectory and investor confidence will depend on its remaining pipeline and strategic decisions regarding remlifanserin.
Why Is ACADIA Pharmaceuticals (ACAD) Advancing Remlifanserin After Its Phase 2 RADIANT Results?
ACADIA Pharmaceuticals reported positive Phase 2 RADIANT data for remlifanserin in Alzheimer’s disease psychosis, showing clinical improvements and a favorable safety profile. The company plans to advance ongoing Phase 3 studies and present detailed data at an upcoming conference. This progress supports ACADIA's strategy to diversify its revenue streams beyond its current key products, despite some concerns about the drug's modest effect size.
Ware Malcomb says construction finished on Acadia Pharmaceuticals’ Princeton office
Design firm Ware Malcomb announced the completion of construction for Acadia Pharmaceuticals Inc.'s 62,600-square-foot East Coast headquarters in Princeton. Ware Malcomb's Princeton office provided interior architecture and design services, focusing on Acadia's brand identity and workplace functionality. The two-level office includes executive spaces, meeting rooms, open work areas, and a dedicated conference center, designed with biophilic principles in mind.
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026
Acadia Pharmaceuticals (NASDAQ: ACAD) stock dropped 19% today after its remlifanserin Phase 2 trial for Alzheimer's disease psychosis narrowly missed its primary endpoint. Despite the setback, management is proceeding with Phase 3 trials, emphasizing encouraging secondary measures and a favorable safety profile. Analysts have adjusted price targets but maintain "Outperform" or "Buy" ratings, with TIKR's valuation model suggesting a potential 54% upside to $34, contingent on continued success of existing drugs and clearer Phase 3 results for remlifanserin.
Why Is Acadia Pharmaceuticals Stock Tumbling Today? - ACADIA Pharmaceuticals (NASDAQ:ACAD)
Acadia Pharmaceuticals' stock is down after its remlifanserin drug for Alzheimer's disease psychosis narrowly missed its primary goal in a Phase 2 trial, though it showed promise in a secondary endpoint and a favorable safety profile. The company plans to proceed with a Phase 3 study using a 60 mg dose. Technically, the stock faces bearish momentum, trading below key moving averages with an oversold RSI, despite an earlier "golden cross" signal.
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026
Acadia Pharmaceuticals (NASDAQ: ACAD) stock fell 19% after its Alzheimer's drug, remlifanserin, narrowly missed its primary endpoint in a Phase 2 trial. Despite the setback, management is pushing forward with Phase 3 trials, supported by a favorable safety profile and strong secondary endpoint results. Analysts have adjusted price targets, with a valuation model suggesting a potential 54% upside to $34 per share based on continued growth of existing drugs DAYBUE and NUPLAZID and successful Phase 3 outcomes for remlifanserin.
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
Acadia Pharmaceuticals announced positive Phase 3 enabling topline results from the Phase 2 RADIANT study of remlifanserin for Alzheimer’s disease psychosis (ADP). The 60 mg dose showed meaningful efficacy trends, narrowly missing the primary endpoint but achieving significance on a key secondary endpoint, with a favorable safety profile. Based on these findings, Acadia plans to continue its Phase 3 program for remlifanserin in ADP, removing the 30 mg dose arm.
Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
Acadia Pharmaceuticals' phase 2 Alzheimer’s disease trial for remlifanserin missed its primary endpoint, but the company and analysts see promising signals for continued development. Despite the near-miss in statistical significance, the drug showed a favorable safety profile and positive trends in secondary endpoints, prompting Acadia to proceed with a phase 3 trial for the 60-mg dose. The company plans to refine enrollment criteria for the phase 3 study to enhance efficacy.
ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint
ACADIA Pharmaceuticals saw its shares drop 10% pre-bell after its Remlifanserin study missed its main endpoint. The article also notes recent activities like the EU approval of their Rett Syndrome drug Daybu and various analyst adjustments to their price targets. The company is focused on neurological and rare disease communities with a pipeline that includes treatments for Alzheimer's disease psychosis and Lewy body dementia psychosis.
Acadia Pharmaceuticals stock tumbles on mixed trial results
Acadia Pharmaceuticals' stock (NASDAQ:ACAD) fell 6% after its Phase 2 RADIANT study for Alzheimer’s disease psychosis narrowly missed its primary endpoint. Despite this, the drug achieved nominal significance on a key secondary endpoint and showed a favorable safety profile, prompting the company to continue its Phase 3 studies while dropping the 30 mg dosage arm. Detailed results will be presented at an upcoming conference in November 2026.
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint
Acadia Pharmaceuticals' shares dropped 6% after its Phase 2 RADIANT study for remlifanserin in Alzheimer's disease psychosis missed its primary endpoint. Although the 60 mg dose showed nominal statistical significance on a key secondary endpoint (CGI-S-ADP), the primary SAPS H+D endpoint was not met. Despite these results, Acadia plans to continue with two ongoing Phase 3 studies, removing the 30 mg dose arm.
ACADIA Pharmaceuticals (ACAD) Looks Undervalued As Pipeline Momentum Keeps The Bull Case Alive
ACADIA Pharmaceuticals (ACAD) appears undervalued with a fair value of $33.25 against its current trading price of $26.76. The company's strong pipeline, including 9 programs and multiple late-stage clinical readouts expected by 2027, is a key driver for its potential future growth and revenue diversification. While recent short-term returns have been mixed, its 90-day and 1-year performance suggest building momentum.
Acadia Pharmaceuticals Announces Preliminary Court Approval of Stockholder Derivative Lawsuit Settlement
Acadia Pharmaceuticals announced the preliminary court approval of a settlement in a stockholder derivative lawsuit. The U.S. federal court granted approval on August 24, 2026, for the case titled Kanner et al. v. Biggar et al. The company is mandated to publish the settlement notice and related documents, which are accessible on its investor relations website.
Acadia Pharmaceuticals announces preliminary court approval of settlement in stockholder derivative action
Acadia Pharmaceuticals has received preliminary court approval for a settlement in a stockholder derivative action. The company is required to publish details of the settlement and stipulation on its investor relations website. Despite ongoing legal proceedings, Acadia's business remains strong, with the stock appearing undervalued and recent European Commission approval for DAYBU, leading to positive analyst ratings and price target increases.
Form 8K ACADIA Pharmaceuticals Inc For: 11 September By Investing.com
This article from Investing.com announces that ACADIA Pharmaceuticals Inc. filed a Form 8K on September 11. The brief piece notes the company's stock symbol ACAD and its current performance. No further details about the content of the 8K filing are provided.
Acadia Pharmaceuticals announces preliminary court approval of settlement in stockholder derivative action
Acadia Pharmaceuticals announced that the U.S. District Court for the Southern District of California has preliminarily approved a settlement in a stockholder derivative action. The company is required to publish details of the settlement and stipulation on its investor relations website. Despite the ongoing legal proceedings, Acadia's business is reported as solid, with the stock appearing undervalued according to InvestingPro analysis, and analysts maintaining positive outlooks due to recent regulatory approvals and pipeline developments.
Form 8K ACADIA Pharmaceuticals Inc For: 11 September By Investing.com
This article reports on the filing of Form 8K by ACADIA Pharmaceuticals Inc. on September 11. It provides a brief mention of the filing without further details on its content. The article also includes various market data and other news headlines from Investing.com.
Acadia Pharmaceuticals announces preliminary court approval of settlement in stockholder derivative action
Acadia Pharmaceuticals has announced that the United States District Court for the Southern District of California has preliminarily approved a settlement in a stockholder derivative action. The settlement was granted preliminary approval on August 24, 2026, and the company is required to publish specific settlement documents on its investor relations website. Despite the legal proceedings, Acadia Pharmaceuticals' business is considered solid, with the stock trading at $27.83, a market capitalization of $4.78 billion, and a "GREAT" financial health score according to InvestingPro.
Form 8K ACADIA Pharmaceuticals Inc For: 11 September By Investing.com
This article reports that ACADIA Pharmaceuticals Inc. filed a Form 8K on September 11. The brief mention indicates a significant event or disclosure by the company. The stock symbol ACAD is noted with a minor positive change.
ACADIA Pharmaceuticals (ACAD) Wins EU Approval For DAYBU, Is The 16% Upside Still There?
ACADIA Pharmaceuticals received EU approval for DAYBU, its treatment for Rett syndrome, opening access across 30 European countries. The company's stock has seen a 30% gain over 90 days, leading to questions about whether the current valuation reflects a stronger business outlook or if sentiment has outpaced fundamentals. Analysts estimate a fair value of $33.25, suggesting a potential 15.7% undervaluation, driven by projected revenue growth and pipeline expansion.
Deutsche Bank Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38
Deutsche Bank has reiterated its Buy rating on ACADIA Pharmaceuticals (ACAD.US) and increased its target price for the company's stock to $38. This adjustment reflects the bank's continued positive outlook on the pharmaceutical firm.
Deutsche Bank raises Acadia Pharma price target after EU approval of Daybu for Rett syndrome.
Deutsche Bank has increased its price target for Acadia Pharmaceuticals to $38, reflecting a 25% potential upside. This adjustment follows the European Commission's approval of Daybu (trofinetide) as the first treatment for Rett syndrome in the EU, opening up a market across 30 European countries for Acadia. Additionally, a 20% year-over-year rise in new prescriptions for Nuplazid supports the company's positive growth outlook.
Deutsche Bank Adjusts ACADIA Pharmaceuticals PT to $38 From $37, Maintains Buy Rating
Deutsche Bank has increased its price target for ACADIA Pharmaceuticals (ACAD) to $38 from $37, while reiterating its Buy rating on the stock. This adjustment comes amidst other analyst activities for ACADIA, including European Commission approval for DAYBUE, its Rett Syndrome drug, and various price target changes from firms like UBS, Morgan Stanley, Oppenheimer, and RBC Capital. The company's Q2 earnings also showed strong Daybue sales, leading to an improved 2026 outlook.
ACADIA Pharmaceuticals: Another Bite At The Alzheimer's Apple (NASDAQ:ACAD)
ACADIA Pharmaceuticals is set to release Phase 2 results for its Alzheimer's psychosis drug, remlifanserin, by October. The author, an Alzheimer's researcher, expresses skepticism about positive outcomes based on the drug's mechanism of action. Despite potential failure, ACADIA's existing approved drugs, Daybue and Nuplazid, provide financial cushioning, mitigating significant downside risk for the company.
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
Acadia Pharmaceuticals announced that the European Commission has granted marketing authorization for Daybu (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. This approval makes Daybu the first and only treatment for this indication in the EU, expanding Acadia's commercial reach across 27 EU member states plus Iceland, Liechtenstein, and Norway. The company will now proceed with pricing and reimbursement negotiations, anticipating further sales growth for Daybu, which is already marketed in the U.S., Canada, and Israel.
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
Acadia Pharmaceuticals has received marketing authorization from the European Commission for Daybu (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. This approval makes Daybu the first and only treatment for this indication in the EU, expanding Acadia's commercial reach across 27 EU member states plus Iceland, Liechtenstein, and Norway. The company will now begin pricing and reimbursement negotiations, supported by positive data from the pivotal phase III LAVENDER study.
EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe
The European Commission has approved Acadia Pharmaceuticals' DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and children aged five and older across the EU, Iceland, Liechtenstein, and Norway. This marks the first approved treatment for Rett syndrome in the EU, though country-specific pricing and reimbursement negotiations are still required. The approval is based on positive results from the Phase 3 LAVENDER study, demonstrating improvement in core Rett syndrome symptoms.
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
The European Commission has approved DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome in the European Union for patients aged five years and older. This approval, based on positive Phase 3 LAVENDER™ study results, marks a significant milestone for Acadia Pharmaceuticals and the Rett syndrome community. Acadia will now begin pricing and reimbursement negotiations to make DAYBU available across the EU.
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
The European Commission has granted marketing authorization for Acadia Pharmaceuticals' DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older within the EU. This approval, based on the Phase 3 LAVENDER™ study, marks a significant milestone for the Rett syndrome community, addressing a profound unmet medical need. Acadia will now pursue pricing and reimbursement negotiations to make DAYBU accessible across the EU and associated countries.
Virtus Advisers LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD
Virtus Advisers LLC has made a new investment in ACADIA Pharmaceuticals Inc., purchasing over 44,000 shares valued at approximately $1.12 million. Other institutional investors like BlackRock and Norges Bank also significantly increased their stakes. Despite insider selling, analysts maintain a "Moderate Buy" consensus for ACADIA Pharmaceuticals, which recently beat earnings estimates.
